AbbVie Rinvoq shows effectiveness for atopic dermatitis in head and neck
by
Contributor since / Followers
Contributor since / Followers
2 months ago
bravo1954/E+ via Getty Images
- A post-hoc analysis found that AbbVie’s (NYSE:ABBV) Rinvoq (upadacitinib) was found to improve moderate-to-severe atopic dermatitis found on the head and neck areas.
- Results showed skin clearance, itch resolution and impact on quality of life at 16 weeks.
- Overall, the analysis of the Measure Up 1 and Measure Up 2 studies showed that more patients with moderate-to-severe atopic dermatitis involving the head and neck involvement Rinvoq at 15 mg or 30 mg doses saw the following compared to placebo at week 16: near complete skin clearance in the head and neck region (EASI Head & Neck Score <1); minimal or no impact on quality of life (DLQI 0/1); and minimal disease activity.